Filing summary
Entity discrepancy: The request identifies Larimar Therapeutics, Inc., but the supplied Form 10-Q is for Zafgen, Inc. This summary reflects the supplied filing, not a Larimar filing. It covers the quarter and six months ended June 30, 2017; filed August 9, 2017.
Business context and reporting period
Zafgen was a clinical-stage biopharmaceutical company developing MetAP2 inhibitors for metabolic diseases, including type 2 diabetes and obesity. Its lead candidate, ZGN-1061, had completed Phase 1. The company reported positive Phase 1 topline results in May 2017 and presented full data in June; it planned to start a 12-week Phase 2 trial in approximately 120 overweight or obese patients with type 2 diabetes in Australia and New Zealand in Q3 2017. The company had no product revenue.
Financial results and liquidity
Amounts are in millions of dollars, except per-share data. The filing reports no revenue, so operating margins are not meaningful.
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $10.528 | $10.163 | $20.205 | $22.660 |
| General and administrative expense | $3.008 | $4.899 | $6.596 | $10.259 |
| Total operating expenses | $13.536 | $15.062 | $26.801 | $32.919 |
| Net loss | $13.347 | $15.028 | $26.358 | $32.764 |
| Basic and diluted loss per share | $0.49 | $0.55 | $0.96 | $1.20 |
- Cash flow: Operating activities used $21.860 million in the first half, versus $32.279 million in 2016. Investing activities provided $22.678 million, mainly from marketable-security maturities and sales net of purchases. Financing activities used $1.444 million, mainly for debt repayments. Cash and cash equivalents declined $0.626 million to $31.726 million.
- Balance sheet at June 30: Cash and cash equivalents were $31.726 million and marketable securities were $74.266 million, totaling approximately $106.0 million in cash, equivalents and securities. Total assets were $108.845 million; current and total liabilities were $9.219 million; stockholders’ equity was $99.626 million.
- Debt: Current notes payable were $2.063 million. The 2014 credit facility was secured by substantially all personal property other than intellectual property, carried an approximately 10.8% effective annual rate, and had no financial covenants. Scheduled principal and interest payments ran through December 2017.
- Management’s liquidity view: The company expected available cash, equivalents and marketable securities to fund operations and capital expenditures for at least one year from the report’s issuance date. It cautioned that assumptions could prove wrong and additional financing might be needed.
Material changes versus prior comparable periods
- First-half net loss narrowed by $6.406 million year over year as total operating expenses fell $6.118 million.
- First-half R&D expense decreased $2.455 million: beloranib spending fell $8.739 million after the program was suspended in July 2016, partly offset by higher ZGN-1061 spending ($7.807 million) and discovery and screening costs ($1.804 million).
- Q2 R&D expense rose $0.365 million year over year, as higher ZGN-1061 and discovery spending more than offset reduced beloranib and unallocated costs.
- First-half G&A expense declined $3.663 million, including lower stock-based compensation, professional fees and personnel costs. The company attributed lower costs in part to its 2016 workforce reduction of approximately 31%.
- Cash and marketable securities together fell from $129.194 million at December 31, 2016 to $105.992 million at June 30, 2017. Marketable securities alone declined from $96.842 million to $74.266 million.
Outlook, risks, contingencies and unusual items
- The company expected significant expenses and operating losses to continue as it advanced ZGN-1061 and conducted early research, and said future funding could require equity, debt, collaborations or licensing arrangements. Financing might be unavailable on acceptable terms; equity financing could dilute shareholders, while partnerships could require relinquishing rights.
- ZGN-1061 Phase 1 results were early-stage: the filing described a favorable safety profile and no observed prothrombotic effects in that trial, but emphasized that early results do not predict later trial outcomes. Safety concerns related to thrombosis and other adverse effects observed with beloranib remained a central development risk.
- The company depended on third parties for clinical trials and drug manufacturing. Trial delays, enrollment challenges, regulatory requirements, supply issues or adverse findings could increase costs or delay development. The company said existing drug-substance inventory was expected to support Phase 2 trials.
- Beloranib-related licensing agreements could require up to $12.3 million in pre-commercialization milestones and up to $12.5 million in commercialization milestones, plus royalties if products were commercialized. No milestones were achieved in the reported periods.
- A securities class action concerning beloranib-related statements had been dismissed with prejudice; the First Circuit affirmed the dismissal on April 7, 2017. The company said it knew of no other material claims as of June 30, 2017.
- Boston office lease extensions were negotiated as of July 31, 2017, adding minimum payments of $0.2 million for the rest of 2017, $0.4 million for each of 2018 and 2019, and $0.2 million for 2020; these amounts were not included in the lease-payment table as of June 30.
- Management reported effective disclosure controls at the reasonable-assurance level and no material change in internal control over financial reporting during Q2. The company reported no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is for Zafgen, Inc., not Larimar Therapeutics, Inc.
- Track Phase 2 trial initiation, enrollment, results and any regulatory feedback for ZGN-1061, especially longer-term safety and thrombotic risk.
- Monitor quarterly cash burn, the stated one-year-plus liquidity runway, and whether additional financing or partnering becomes necessary.
- Review debt repayment and maturity status, and the financial terms and obligations associated with the credit facility.
- Assess the impact of continuing clinical, manufacturing and licensing commitments, as well as the Boston lease extensions, on future cash needs.